Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Mar 2019 Status changed from recruiting to completed.
- 12 Dec 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018.
- 12 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.